Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases

Abstract

Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compounds in combination with anti-viral, anti-proliferative and anti-inflammatory compounds. Vitamin B12 compounds are administered separately, simultaneously or in combination with anti-viral, anti-proliferative and/or anti-inflammatory compounds to provide an enhanced therapeutic effect for treating viral, proliferative and inflammatory diseases.

1 . A pharmaceutical composition for the treatment of a disease selected from the group consisting of: viral diseases; proliferative diseases; inflammatory diseases; proliferative and inflammatory diseases; proliferative and viral diseases; viral and inflammatory diseases; and proliferative, viral and inflammatory diseases; comprising: (i) At least one vitamin B12 compound; and (ii) At least one second compound selected from the group consisting of: an anti-viral compound; an anti-proliferative compound; and an anti-inflammatory compound.  
     
     
         2 . A pharmaceutical composition of  claim 1  for the treatment of proliferative diseases comprising: (i) At least one vitamin B12 compound; and (ii) At least one anti-proliferative compound.  
     
     
         3 . A pharmaceutical composition of  claim 1  for the treatment of viral diseases comprising: (i) At least one vitamin B12 compound; and (ii) At least one anti-viral compound.  
     
     
         4 . A pharmaceutical composition of  claim 1  for the treatment of inflammatory diseases comprising: (i) At least one vitamin B12 compound; and (ii) At least one anti-inflammatory compound.  
     
     
         5 . The pharmaceutical composition of  claim 2 , wherein the anti-proliferative compound is interferon.  
     
     
         6 . The pharmaceutical composition of  claim 3 , wherein the anti-viral compound is interferon.  
     
     
         7 . The pharmaceutical composition of  claim 4 , wherein the anti-inflammatory compound is interferon.  
     
     
         8 . A pharmaceutical composition for the treatment of a virus selected from the group consisting of Hepatitis B, hepatitis C, herpes simplex virus type 2 and vesticular stomatitis virus comprising: (i) At least one vitamin B12 compound; and (ii) At least one interferon compound.  
     
     
         9 . A pharmaceutical composition of  claim 2  wherein the proliferative disease is cancer.  
     
     
         10 . A pharmaceutical composition of  claim 2  wherein the proliferative disease is an astrocytoma or glioma.  
     
     
         11 . A pharmaceutical composition of  claim 8  wherein the virus is hepatitis C.  
     
     
         12 . A pharmaceutical composition of  claim 9  comprising: (i) At least one vitamin B12 compound; and (ii) Paclitaxel.  
     
     
         13 . A pharmaceutical composition of  claim 10  comprising: (i) At least one vitamin B12 compound; and (ii) Paclitaxel.  
     
     
         14 . A pharmaceutical composition of  claim 10  comprising: (i) At least one vitamin B12 compound; and (ii) At least one interferon compound.  
     
     
         15 . A pharmaceutical composition of  claim 1  for the treatment of multiple sclerosis comprising: (i) Vitamin B12; and (ii) A peptide selected from the group consisting of P16, S-3, S-7, P-32, V-2 and V-3.  
     
     
         16 . A pharmaceutical composition of  claim 8  wherein the virus is Hepatitis B and comprising: (i) Vitamin B12; and (ii) Interferon  
     
     
         17 . (canceled)  
     
     
         18 . A method of treating a disease selected from the group consisting of viral, proliferative, and inflammatory diseases comprising the step of administering to a patient the pharmaceutical composition of  claim 1 .  
     
     
         19 . A method of  claim 18  wherein the disease is hepatitis B or hepatitis C.  
     
     
         20 . A method of treating a disease selected from the group consisting of viral, proliferative and inflammatory diseases comprising the steps of administering to a patient, either together, or separately: (a) At least one Vitamin B12 compound; and (b) At least one compound selected from the group consisting of: an anti-viral compound, an anti-proliferative compound, and an anti-inflammatory compound.  
     
     
         21 . The method of  claim 18  wherein the dose of Vitamin B12 compound is between 10-2500 mg.  
     
     
         22 . The method of  claim 18  wherein the dose of the anti-viral, anti-proliferative or anti-inflammatory compound is equivalent to the therapeutic dose range of said anti-viral, anti-proliferative, or anti-inflammatory compound when used alone.  
     
     
         23 . The method of  claim 18  wherein the dose of anti-viral, anti-proliferative or anti-inflammatory compound is less than the therapeutic dose range of said anti-viral, anti-proliferative, or anti-inflammatory compound when used alone.  
     
     
         24 . (canceled)